Search

Zentalis Pharmaceuticals Inc

Lezárt

3.87 -0.26

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

3.81

Maximum

3.92

Fő mutatók

By Trading Economics

Bevétel

-42M

-78M

Egy részvényre jutó nyereség

-0.59

Munkavállalók

106

EBITDA

-42M

-77M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+127.58% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. nov. 6.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

25M

356M

Előző nyitás

4.13

Előző zárás

3.87

Zentalis Pharmaceuticals Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 26. 23:56 UTC

Fluence Energy Inc shares are higher in after-market trading. Broader market context includes recent PCE price index data indicating ongoing inflationary pressures.

2026. aug. 26. 23:56 UTC

Correlated Moves
Social Media

Tesla shares are trading higher in after-market hours, supported by increased institutional holdings from major investors and a broader market uptick.

2026. aug. 26. 23:56 UTC

Shares of Stanley Black & Decker Inc rose modestly in after-market trading, settling at a cumulative return of 0.33% since Wednesday's close.

2026. aug. 26. 23:56 UTC

Shares of Synchrony Financial are lower in after-market trading, moving from an early high to a low during the session.

2026. aug. 26. 23:56 UTC

RTX Corp. shares are trading lower in after-market hours, with significant volatility noted since Wednesday's close and prices below the 20-day moving average.

2026. aug. 26. 23:56 UTC

Macro Event

EUR/AUD trades lower as Australia's July inflation rate declines to 3.5%, exceeding expectations. The currency pair remains near the lower end of its one-month range.

2026. aug. 26. 23:56 UTC

Ralph Lauren Corp shares are lower in after-market hours, continuing a trend from regular trading. The stock remains below its 20-day moving average.

2026. aug. 26. 23:56 UTC

News

Constellation Brands reported first-quarter results that beat expectations, driven by beer sales. The company also reaffirmed EPS guidance and plans a $100 million investment.

2026. aug. 26. 23:56 UTC

Cheniere Energy shares are trading lower in after-market hours. No specific news was identified to explain this price movement.

2026. aug. 26. 23:52 UTC

AT&T Inc shares are lower in after-market hours with no specific news identified. Broader market data on rising consumer prices may influence investor sentiment.

2026. aug. 26. 23:52 UTC

MARA Holdings Inc. shares are higher in after-market hours, supported by robust economic data and easing crude oil prices, reflecting a positive market trend.

2026. aug. 26. 23:52 UTC

Correlated Moves

The SGD/CHF is trading higher, supported by a recent rise in USD/CHF. It remains near the upper end of its one-month trading range.

2026. aug. 26. 23:52 UTC

The Swiss franc is trading lower against the South African rand during Wednesday's session, remaining near the lower end of its one-month range.

2026. aug. 26. 23:51 UTC

The Nikkei 225 Index is trading higher in after-market hours, continuing a trend of upward movement following Wednesday's close.

2026. aug. 26. 23:51 UTC

Ladder Capital Corp shares are higher in after-market trading, moving up from earlier lows and trading above its 20-day moving average. No specific news identified.

2026. aug. 26. 23:51 UTC

Correlated Moves

Alpha and Omega Semiconductor rises in after-hours trading, recovering from an earlier dip. The stock advanced sharply since Wednesday's close, tracking semiconductor sector gains.

2026. aug. 26. 23:51 UTC

Correlated Moves

PagerDuty Inc. shares are higher in after-market hours, driven by strong overall market momentum and Salesforce Inc.'s significant gain. Positive economic data supports this trend.

2026. aug. 26. 23:51 UTC

Cabaletta Bio Inc shares are lower in after-market trading, following a decline earlier in the session. No specific news was identified to explain the movement.

2026. aug. 26. 23:51 UTC

JetBlue Airways Corp shares are higher in after-market trading, reflecting broader market gains amid positive economic data on consumer prices and durable goods orders.

2026. aug. 26. 23:51 UTC

Community Financial System Inc shares are higher in after-market hours, recovering from earlier lows. The stock remains below its 20-day moving average.

2026. aug. 26. 23:51 UTC

Beam Therapeutics Inc shares are higher in after-market hours, reflecting a broadly positive market trend. The stock is near the upper end of its one-month range.

2026. aug. 26. 23:51 UTC

Arbor Realty Trust is trading higher in after-market hours, advancing from Wednesday's close. Shares earlier pulled back but remain above the prior close.

2026. aug. 26. 23:51 UTC

Yelp Inc shares are higher in after-market trading, recovering from an earlier dip. The stock remains below its 20-day moving average.

2026. aug. 26. 23:51 UTC

PENN Entertainment Inc. shares rose in after-market trading, gaining modestly since Wednesday's close despite remaining below its 20-day moving average.

2026. aug. 26. 23:51 UTC

U.S. markets gain momentum as inflation data reveals slight consumer price rise, while UK car production declines and copper prices surge amid strong demand.

2026. aug. 26. 23:51 UTC

U.S. equity indices rise amid positive global sentiment and inflation data, while investors await Nvidia earnings and navigate geopolitical tensions affecting oil prices.

2026. aug. 26. 23:51 UTC

Asia equity markets rise on falling crude oil prices and tech stock gains, while caution prevails ahead of U.S. inflation data and Fed Chair's speech.

2026. aug. 26. 23:51 UTC

Mixed trading in European equities as easing inflation concerns clash with rising energy prices and UK economic woes.

2026. aug. 26. 23:51 UTC

Brazil's Q2 GDP Growth Rate Expected to Rise by 0.8% Amidst Global Economic Challenges, Following a Strong 1.1% Expansion in Q1

2026. aug. 26. 23:51 UTC

Market Cautiously Awaits Insights from Jackson Hole Symposium as Inflation Concerns and Fed Dissent Shape Economic Outlook.

Társak összehasonlítása

Árváltozás

Zentalis Pharmaceuticals Inc Előrejelzés

Célár

By TipRanks

127.58% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 8.83 USD  127.58%

Magas 11 USD

Alacsony 5 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Zentalis Pharmaceuticals Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

5

Vétel

1

Tartás

0

Eladás

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat